Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology and pharmaceutical company focused on therapies for pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and other serious conditions, as well as technologies to expand the availability of transplantable organs. This news page aggregates company announcements, clinical updates, financial disclosures, and conference presentations related to UTHR.
Recent news highlights include detailed results from the TETON-2 phase 3 study of nebulized Tyvaso (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis, where United Therapeutics reported that the trial met its primary efficacy endpoint and achieved statistically significant improvements in several secondary endpoints. The company has also announced the first clinical xenotransplantation of its investigational UKidney xenokidney in the EXPAND study for patients with end-stage renal disease, reflecting its stated public benefit purpose of expanding access to transplantable organs.
Investors and followers of UTHR can review press releases on quarterly financial results, including product-level revenue disclosures for Tyvaso DPI, nebulized Tyvaso, Remodulin, Orenitram, Unituxin, Adcirca, and other items. Additional updates cover accelerated share repurchase agreements, stock incentive plan changes, and participation in major investor conferences hosted by firms such as J.P. Morgan, UBS, Jefferies, and Bernstein.
For those tracking developments in pulmonary hypertension, interstitial lung disease, xenotransplantation, and the company’s public benefit corporation activities, this news feed offers a centralized view of United Therapeutics’ clinical data presentations, regulatory milestones, and corporate actions. Bookmark this page to quickly access new UTHR press releases and related market-moving information as they are published.
United Therapeutics reported strong Q1 2025 financial results with total revenues reaching $794.4 million, marking a 17% increase from Q1 2024. The company's flagship product Tyvaso led growth with total revenues of $466.3 million, up 25% year-over-year.
Key highlights include net income of $322.2 million and earnings per diluted share of $6.63. Tyvaso DPI showed exceptional performance with a 33% revenue increase to $302.5 million. The growth was driven by increased patient numbers and Medicare Part D benefit redesign implementation.
The company announced progress in their organ transplant alternatives program, with planned FDA applications for UHeart and UThymoKidney products. They also expect results from the TETON 2 trial in idiopathic pulmonary fibrosis and plan to commence UKidney human clinical studies.
United Therapeutics (UTHR) has announced its participation in the American Thoracic Society (ATS) International Conference in San Francisco, May 16-21, 2025, where it will present clinical data across its commercial and development portfolio.
Key presentations include interim long-term data from the ralinepag phase 3 ADVANCE EXTENSION open-label study and preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis. The company will showcase research through various sessions, including thematic posters, mini-symposia, and discussion sessions.
The company is also sponsoring several events including the Respiratory Innovation Summit, the ATS Research Program Benefit Networking Event, and hosting the Jenesis Innovative Research Awards™ Ceremony.
United Therapeutics (NASDAQ: UTHR) has announced it will release its first quarter 2025 financial results before market opening on Wednesday, April 30, 2025. The company will issue a detailed press release at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time.
The webcast will be available through the company's investor relations website and will remain accessible for replay for one year. United Therapeutics operates as a public benefit (PBC), focusing on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.
United Therapeutics (UTHR) announced the presentation of ten posters and presentations across its commercial and development portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting taking place April 27-30, 2025 in Boston.
The presentations cover various topics including xenotransplantation developments, pharmacokinetic studies of Ralinepag, cardiac xenotransplantation outcomes, and pulmonary hypertension research. Key highlights include studies on multi-gene-edited pig lungs, pig-to-baboon lung transplantation, and safety data on low-dose oral Treprostinil in PH-HFpEF patients.
The company will also host a sponsored symposium titled 'The Pros, The Cons, the Wicked Good EVLP Debates' featuring experts from leading medical institutions discussing ex vivo lung perfusion.
United Therapeutics (NASDAQ: UTHR) has been recognized as one of the Fortune 100 Best Companies to Work For in 2025, ranking #73 on the prestigious list. The recognition comes from Great Place to Work® and Fortune magazine, based on confidential feedback from over 1.3 million U.S. employees.
As the first publicly-traded biotech company to become a public benefit (PBC), United Therapeutics focuses on developing novel pharmaceutical therapies and expanding transplantable organ availability. The company's placement on the list reflects its commitment to creating a high-trust workplace environment, measured through Great Place To Work's Trust Index™ Survey.
Michael Benkowitz, President & COO, emphasized the company's goal of being a destination employer, while Alyssa Friedrich, EVP and Chief People Officer, highlighted their focus on creating an environment where employees feel valued and inspired.
United Therapeutics (UTHR) has announced its participation in the upcoming Leerink Partners Global Healthcare Conference 2025 in Miami Beach. CFO James Edgemond will present a company update in a fireside chat on March 11, 2025, from 10:00-10:30 AM EDT.
The session will be accessible through a live webcast on the company's investor relations website, with a recorded version available for 90 days afterward. United Therapeutics, notably the first publicly-traded biotech/pharmaceutical public benefit (PBC), focuses on two main objectives:
- Developing novel pharmaceutical therapies
- Creating technologies to expand transplantable organ availability
United Therapeutics (UTHR) reported strong financial results for Q4 and full year 2024, with annual revenues reaching a record $2.88 billion, representing 24% growth over 2023.
The company's Tyvaso product line led growth with total revenues of $1.62 billion in 2024, up 31% from 2023. This growth was primarily driven by Tyvaso DPI's increased patient adoption and enhanced commercial utilization following Part D redesign under the Inflation Reduction Act.
Key clinical developments include: fully enrolled TETON studies in idiopathic pulmonary fibrosis with data expected in H2 2024, upcoming ralinepag data in 2025, and FDA clearance for the first potential registration-enabling xenotransplantation study with UKidney. The company also completed a $1 billion accelerated share repurchase program in 2024, resulting in 3,547,374 shares repurchased.
United Therapeutics (UTHR) has announced that President and COO Michael Benkowitz will present at the TD Cowen 45th Annual Health Care Conference in Boston. The fireside chat session is scheduled for March 3, 2025, from 1:50 p.m. to 2:20 p.m. EST.
The presentation will be accessible through a live webcast on the company's website, with a recorded version available for 90 days afterward. United Therapeutics, operating as a public benefit (PBC), focuses on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.
The company emphasizes its unique position as the first publicly-traded biotech/pharmaceutical PBC, highlighting its commitment to innovation for unmet medical needs while maintaining a dual focus on patient care and stakeholder benefits.
United Therapeutics (UTHR) has announced it will release its fourth quarter and full year 2024 financial results before market open on Wednesday, February 26, 2025. The detailed quarterly results will be published via press release at approximately 6:30 a.m. Eastern Time.
The company will host a public webcast at 9:00 a.m. Eastern Time on the same day, which will be accessible through United Therapeutics' investor relations website. A replay of the webcast will remain available for one year. United Therapeutics operates as a public benefit (PBC), focusing on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.